Risk-Based Approach for Defining Retest Dates for Active Pharmaceutical Ingredients and Excipients

被引:0
|
作者
Charoo, Naseem A. [1 ]
Akanji, Omotayo [2 ]
Rahman, Ziyaur [3 ]
Khan, Aqeel A. [4 ]
Badshah, Aqal [4 ]
机构
[1] Aramed, 216 Lab Complex,Dubai Sci Pk,POB 478861, Dubai, U Arab Emirates
[2] Katchey Labs, 26 Adeniyi,Adeniyi Jones Ave, Ogba 101233, Ikeja, Nigeria
[3] Texas A&M Univ, Irma Lerma Rangel Coll Pharm, Texas A&M Hlth Sci Ctr, College Stn, TX 77843 USA
[4] Adcan Pharma LLC, ICAD, POB 9824, Abu Dhabi, U Arab Emirates
关键词
retest; risk assessment; critical material attributes; critical quality attributes; shelf life; PARTICLE-SIZE; QUALITY; SEGREGATION; FORMS; FLOWABILITY; STABILITY; BEHAVIOR; DESIGN; IMPACT; MODEL;
D O I
10.3390/ph17070903
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug substances and excipients must be stored in recommended storage conditions and should comply with their specifications during the retest period for their use in the manufacture of drug products. The ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) and WHO (World Health Organization) regulatory guidelines mandate that after the retest period, the drug substances must be retested for compliance with the specification and then used immediately in the manufacture of the finished product. Although these substances can be retested multiple times, an emphasis is placed on immediate use following a retest and compliance with standards. The phrase "used immediately" is ambiguous and is left for interpretation. In this article, we will look at the various processes that must be completed to determine the retest date. In addition, we present a risk-based method for establishing retest dates and the time during which material can be used.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] A risk-based approach
    Huggett, RJ
    ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 1996, 15 (01) : 3 - 3
  • [22] Active Risk-Based Investing
    Jurczenko, Emmanuel
    Teiletetche, Jerome
    JOURNAL OF PORTFOLIO MANAGEMENT, 2018, 44 (03): : 56 - 65
  • [23] FDA's pharmaceutical quality initiatives: Implementation of a modern risk-based approach
    FDA
    不详
    不详
    不详
    不详
    不详
    不详
    不详
    不详
    Pharm. Technol., 2008, 5 (54-72):
  • [24] Heavy metals testing in active pharmaceutical ingredients: an alternate approach
    Raghuram, P.
    Raju, I. V. Soma
    Sriramulu, J.
    PHARMAZIE, 2010, 65 (01): : 15 - 18
  • [25] A model for risk-based monitoring of contaminants in feed ingredients
    van der Fels-Klerx, H. J.
    Adamse, P.
    de Jong, J.
    Hoogenboom, R.
    de Nijs, M.
    Bikker, P.
    FOOD CONTROL, 2017, 72 : 211 - 218
  • [26] A systematic reactor design approach for the synthesis of active pharmaceutical ingredients
    Emenike, Victor N.
    Schenkendorf, Rene
    Krewer, Ulrike
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 126 : 75 - 88
  • [27] Risk-Based Manufacture of Pharmaceutical Products.
    Mahadevan, B.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2011, 52 : S27 - S27
  • [28] Adopting a risk-based approach
    Yohe, Gary
    Leichenko, Robin
    CLIMATE CHANGE ADAPTATION IN NEW YORK CITY: BUILDING A RISK MANAGEMENT RESPONSE, 2010, 1196 : 29 - 40
  • [29] Risk-based approach for method development in pharmaceutical quality control context: A critical review
    Deidda, Riccardo
    Orlandini, Serena
    Hubert, Philippe
    Hubert, Cedric
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 161 : 110 - 121
  • [30] Risk-based principles for defining and managing water security
    Hall, Jim
    Borgomeo, Edoardo
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES, 2013, 371 (2002):